CIK 0001840233 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Xilio Therapeutics, Inc.
Sign in to watch- Ticker
- XLO
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 851623397
- Phone
- 617-833-1027
- Business address
- 828 WINTER STREET, WALTHAM, MA, 02451
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 8 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-10-01 | Houvras Yariv CHIEF MEDICAL OFFICER | Grant or award · Stock Option (right to buy) | +105,000 | 105,000 | ||
| 2026-06-11 | Curran Daniel J. Director | Grant or award · Stock Option (right to buy) | +5,000 | 5,000 | ||
| 2026-06-11 | Shannon James Samuel Director | Grant or award · Stock Option (right to buy) | +5,000 | 5,000 | ||
| 2026-06-11 | Bello Akintunde Olatokumbo Director | Grant or award · Stock Option (right to buy) | +5,000 | 5,000 | ||
| 2026-06-11 | Xu Yuan Director | Grant or award · Stock Option (right to buy) | +5,000 | 5,000 | ||
| 2026-06-11 | ROSS ROBERT W. Director | Grant or award · Stock Option (right to buy) | +5,000 | 5,000 | ||
| 2026-06-11 | Bonstein Sara Director | Grant or award · Stock Option (right to buy) | +5,000 | 5,000 | ||
| 2026-06-11 | Brennan Aoife Director | Grant or award · Stock Option (right to buy) | +5,000 | 5,000 | ||
| 2026-04-15 | Blanchard Cheryl R Director | Grant or award · Stock Option (right to buy) | +10,000 | 10,000 | ||
| 2026-03-26 | Shannon James Samuel Director | Purchase | +5,000 | $8.79 | $44K | 10,000 |
| 2026-02-13 | GILEAD SCIENCES, INC. 10% owner | Purchase · Prefunded Warrants (right to buy) | +3,739,000 | $0.53 | $2.0M | 40,384,266 |
| 2026-01-02 | Brennan Kevin M. SVP, FINANCE AND ACCOUNTING | Sale 10b5-1 | −1,826 | $0.64 | $1K | 6,371 |
| 2026-01-02 | Frankenfield Christopher James Chief Financial Officer | Sale 10b5-1 | −7,030 | $0.64 | $5K | 24,766 |
| 2026-01-01 | Luptakova Katarina CHIEF MEDICAL OFFICER | Option exercise | +16,625 | 33,250 | ||
| 2026-01-01 | Luptakova Katarina CHIEF MEDICAL OFFICER | Option exercise · Restricted Stock Units | −16,625 | 33,250 | ||
| 2026-01-01 | Brennan Kevin M. SVP, FINANCE AND ACCOUNTING | Option exercise 10b5-1 | +5,000 | 8,197 | ||
| 2026-01-01 | Brennan Kevin M. SVP, FINANCE AND ACCOUNTING | Option exercise · Restricted Stock Units 10b5-1 | −5,000 | 10,000 | ||
| 2026-01-01 | Frankenfield Christopher James Chief Financial Officer | Option exercise 10b5-1 | +19,375 | 31,796 | ||
| 2026-01-01 | Frankenfield Christopher James Chief Financial Officer | Option exercise · Restricted Stock Units 10b5-1 | −19,375 | 38,750 | ||
| 2026-01-01 | Russo Rene PRESIDENT AND CEO | Option exercise | +44,250 | 325,422 |
Page 1 of 12 · 224 trades